Papers
Research literature with structured metadata.
Trials
Registered studies by status, phase, and compound.
Topics
Indications and themes psychedelics are researched for.
Compounds
Evidence across molecules with rich data.
Countries
Regulation, access, and research activity by region.
Stakeholders
Organizations shaping the space across research, policy, and funding.
People
Investigators, clinicians, and authors with mapped output.
Courses
Training programs and certifications across modalities.
Events
Conferences, workshops, and convenings by date and focus.
Research recaps
Monthly evidence summaries with key takeaways.
Map of research
Landscape view of trials, compounds, and outcomes.
Newsletter
Weekly or daily updates on trials, publications, analysis, and more.
Research Groups
Worldwide map of psychedelic research centres by region.
Research Network
Interactive co-authorship map of psychedelic researchers.
Top papers
Find needles in the haystack of psychedelic research per topic.
This systematic review finds that postnatal MDMA administration produces prosocial behaviours and may alleviate social impairments in autism models, with the strongest evidence coming from animal studies. Clinical trials are now under way, but larger and longer studies are needed to confirm whether MDMA or MDMA-like compounds can treat social deficits in ASD.
This review (2017) studied research literature on psychedelics and dreaming to systematically compare these two states of consciousness. It highlighted the broad overlap between dreaming and psychedelic states supporting the perception that psychedelics acutely affect dreamlike subjective experiences that may show long-term beneficial responses to psychosocial functioning and well-being.
This comprehensive review (2015) summarizes the chemical characterization, pharmacology, and toxicity of New Psychoactive Substances from the published literature, as well as information gathered from non-peer-reviewed sources, such as drug forums. They provide an overview of useful information, such as reported death cases, for public health workers.
This review (24 studies; n=416) found that ketamine is a reliable fast-acting anti-depressant for patients suffering from treatment-resistant depression (TRD). Long-term effects, however, remain to be studied.